Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (iCDC) therapy in patients with ischemic cardiomyopathy, and to explore its potential as a novel therapeutic strategy for this disease.
Official title: Safety and Efficacy of FAP-Targeted Immunosuppressive CAR-DC in the Treatment of Ischemic Cardiomyopathy
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-05-21
Completion Date
2029-04-01
Last Updated
2026-07-02
Healthy Volunteers
No
Conditions
Interventions
autologus FAP-targeted immunosuppressive CAR-DCs (iCDC)
Each subject receives FAP-targeted immunosuppressive CAR-DCs by intravenous infusion after enrollment.
Standard medical treatment
Participants receive standard medical treatment for ischemic cardiomyopathy according to current clinical practice and guideline-directed medical therapy. No iCDC therapy is administered in this arm.
Locations (1)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang / 浙江, China